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Abstract
Oleoylethanolamide (OEA) is an agonist of the peroxisome proliferator-activated receptor α (PPARα) and has
been described to exhibit neuroprotective properties when administered locally in animal models of several
neurological disorder models, including stroke and Parkinson’s disease. However, there is little information
regarding the effectiveness of systemic administration of OEA on Parkinson’s disease. In the present study,
OEA-mediated neuroprotection has been tested on in vivo and in vitro models of 6-hydroxydopamine
(6-OH-DA)-induced degeneration. The in vivo model was based on the intrastriatal infusion of the neurotoxin
6-OH-DA, which generates Parkinsonian symptoms. Rats were treated 2 h before and after the 6-OH-DA treat-
ment with systemic OEA (0.5, 1, and 5mg/kg). The Parkinsonian symptoms were evaluated at 1 and 4 wk after
the development of lesions. The functional status of the nigrostriatal system was studied through tyrosine-hydro-
xylase (TH) and hemeoxygenase-1 (HO-1, oxidation marker) immunostaining as well as by monitoring the
synaptophysin content. In vitro cell cultures were also treated with OEA and 6-OH-DA. As expected, our results
revealed 6-OH-DA induced neurotoxicity and behavioural deﬁcits; however, these alterations were less severe in
the animals treated with the highest dose of OEA (5mg/kg). 6-OH-DA administration signiﬁcantly reduced the
striatal TH-immunoreactivity (ir) density, synaptophysin expression, and the number of nigral TH-ir neurons.
Moreover, 6-OH-DA enhanced striatal HO-1 content, which was blocked by OEA (5mg/kg). In vitro, 0.5 and
1 μM of OEA exerted signiﬁcant neuroprotection on cultured nigral neurons. These effects were abolished after
blocking PPARα with the selective antagonist GW6471. In conclusion, systemic OEA protects the nigrostriatal
circuit from 6-OH-DA-induced neurotoxicity through a PPARα-dependent mechanism.
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Introduction
Fatty acid acylethanolamides are endogenous lipid modu-
lators generated by the cleavage of the speciﬁc mem-
brane phospholipid, N-acylphosphatidyl ethanolamide
(Piomelli, 2003). These lipids include, among others,
oleoylethanolamide (OEA) and palmitylethanolamide
(PEA) (Rodriguez de Fonseca et al., 2001; Fu et al., 2003;
Lo Verme et al., 2005). Both OEA and PEA are potent
endogenous ligands for peroxisome proliferator-activated
receptor α (PPARα), a nuclear receptor involved in the
transcriptional regulation of lipid metabolism, neuroplas-
ticity and inﬂammation (Rodriguez de Fonseca et al., 2001;
Fu et al., 2003; Lo Verme et al., 2005). Although OEA
might act through alternative receptors, including the
transient receptor potential vanilloid subtype 1 (TRPV1)
(Wang et al., 2005; Thabuis et al., 2008) or the G protein-
coupled receptor 119 (GPR119) (Overton et al., 2006), its
main actions are mediated through the activation of
Address for correspondence: Dr F. R. de Fonseca, Laboratorio de Medicina
Regenerativa, Instituto IBIMA-Unidad de Gestión Clínica de Salud
Mental, Hospital Carlos Haya de Málaga, 29010 Málaga, Spain.
Tel.: +34 669 426548 Fax: +34 952 614012
Email: fernando.rodriguez@fundaciónimabis.org
* These two authors contributed equally to the present study.
International Journal of Neuropsychopharmacology (2014), 17, 455–468. © CINP 2013
doi:10.1017/S1461145713001259
ARTICLE
PPARα receptors. Several reports have indicated the phy-
siological relevance of OEA as a modulator of feeding,
pain, inﬂammation, glucose homeostasis and the regu-
lation of metabolism (Rodriguez de Fonseca et al., 2001;
Fu et al., 2003; Bordet et al., 2006; Suardiaz et al., 2007;
Thabuis et al., 2008; Pavon et al., 2010).
PPARα plays a prominent role in inﬂammatory and oxi-
dant responses (Peters et al., 1997; Aoyama et al., 1998;
Cuzzocrea et al., 2006), and its activation negatively regu-
lates the transcription of inﬂammatory response genes
(Schmidt et al., 1999; Delerive et al., 2001; Lleo et al.,
2007; Kono et al., 2009). PPARα ligands, such as synthetic
fenoﬁbrates, have been shown to protect against cerebral
ischemia by anti-inﬂammatory and antioxidant mechan-
isms (Deplanque et al., 2003; Bordet et al., 2006), and
these effects are completely absent in PPARα-deﬁcient
mice (Deplanque et al., 2003). The synthesis of the endo-
genous PPARα ligand, OEA, is induced on demand after
the local accumulation of stimuli in the brain following an
injury, such as cellular stress (Berdyshev et al., 2000;
Schabitz et al., 2002; Walter et al., 2002) and tissue dam-
age following ischemia (Schabitz et al., 2002). In fact,
the neuroprotective effects of the locally administered
agonist OEA and related compounds have been described
in animal models of neurological disorders (Lombardi
et al., 2007; Sun et al., 2007; Bisogno et al., 2008; Galan-
Rodriguez et al., 2009). The therapeutic properties of
OEA and its actions on PPARα receptors point to a poten-
tial role for this signaling system in neurodegenerative
disorders where inﬂammation and oxidative stress
take place (Beltowski et al., 2002; Lo Verme et al., 2005;
Suardiaz et al., 2007), such as autoimmune encephalo-
myelitis (Diab et al., 2004), multiple sclerosis (Racke
et al., 2006) and Parkinson’s disease (Galan-Rodriguez
et al., 2009).
Concerning Parkinson’s disease, the in vivo retrograde
model of nigrostriatal dopaminergic cell degeneration is
based on the intrastriatal administration of the neurotoxin
6-hydroxydopamine (6-OH-DA), which leads to an ex-
tended and progressive cell death in the substantia nigra
(Sauer and Oertel, 1994). Moreover, the insult induces
a substantial destruction of nigrostriatal dopaminergic
neurons, which is associated with a vigorous inﬂamma-
tory response (Cicchetti et al., 2002; Na et al., 2010). Inter-
estingly, oxidative stress and neuroinﬂammation are early
events linked to the pathogenesis of Parkinson’s disease,
a degenerative neurological disorder where the nigro-
striatal dopaminergic system is severely damaged ( Jenner
and Olanow, 1998; Fernandez-Espejo, 2004). In this sense,
PPARα is known to be expressed by dopaminergic
neurons of the substantia nigra and the spiny neurons
of the dorsal striatum (Kainu et al., 1994; Cullingford
et al., 1998; Moreno et al., 2004; Galan-Rodriguez et al.,
2009). Because PPARα receptors are involved in oxidative
stress and inﬂammation, which are metabolic situations
common to toxic insults induced by neurotoxins
(Beltowski et al., 2002; Kreisler et al., 2007), OEA could
exert neuroprotective effects against dopamine depletion
in the nigrostriatal circuit. OEA might modulate 6-OH-
DA-induced neurotoxicity damage of dopaminergic
neurons (Ungerstedt, 1968; Schwarting and Huston,
1996) because this neurotoxin acts through the generation
of reactive oxygen species (ROS) (Cohen et al., 1976;
Cadet et al., 1989; Ben-Shachar et al., 1991). Recently,
we have demonstrated that local administration of OEA
exerts dose-dependent neuroprotective effects on nigral
dopaminergic neurons after intra-striatal injection of
6-OH-DA (Galan-Rodriguez et al., 2009). However, the
potentially neuroprotective effects of systemic OEA on
the nigrostriatal circuit after 6-OH-DA lesions are still
not known. These effects deserve to be studied because
systemic treatment is the most widely used route of
administration for pharmacological therapies. There is
only one report published recently on the neuroprotective
actions of OEA administered systemically in a mouse
model of brain ischemia (Zhou et al., 2012).
Taking these data into consideration, the main ob-
jectives of the present study were the following: (1) to
evaluate the neuroprotective effects of systemic OEA
treatment in 6-OH-DA-induced lesions with a rat retro-
grade model of Parkinsonism and (2) to assess the neuro-
protective effects of OEA treatment in 6-OH-DA-induced
damage with in vitro cell culture and the relationship be-
tween the neuroprotective effects and PPARα receptors.
Methods
Animals
The experiments were performed on male Wistar rats
(Charles Rivers, Spain) weighing 275–325 g and 12–
15 wk old. The animals were housed in a humidity-
and temperature-controlled (22±1 °C) vivarium on a 12 h
light/dark cycle. Water and standard laboratory food
were available ad libitum. All experiments were per-
formed in compliance with the European Animal Re-
search Laws (European Communities Council Directives
2010/63/UE, 90/219/CEE, Regulation (EC) no 1946/2003)
and Spanish National and Regional Guidelines for
Animal Experimentation and use of genetically modiﬁed
organisms (RD 53/2013, 178/2004, 320/2010, and Ley 32/
2007, 9/2003).
Drugs
For in vivo studies, OEA was synthesized in our labora-
tory, as previously described, (Giuffrida et al., 2000) and
administered by i.p. injection in a vehicle solution consist-
ing of 10% dimethylsulfoxide (DMSO) in distilled water.
OEA was administered at doses of 20mg/kg for microdi-
alysis and 0.5, 1 and 5mg/kg for behavioural tests in a
volume of 1ml/kg body weight. It was administered 2 h
before and after the administration of 6-OH-DA. To in-
duce striatal lesions, 6-OH-DA (Sigma-Aldrich, USA)
was dissolved in 0.2% ascorbic acid in saline. 6-OH-DA
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was centrally injected at 5 μg/μl in a volume of 2 μl (n=
25–30 rats per experimental group).
Regarding the in vitro studies, OEA was employed
in cultures at doses of 30 and 300 nM, and 1.5, 3 and
6 μM dissolved in a vehicle consisting of 10% ethanol in
Neurobasal® medium (Invitrogen, USA). 6-OH-DA was
used at 40 and 60 μM dissolved in 0.15% ascorbic acid in
saline, and the 6-OH-DA concentrations used were 8.22
and 12.34 μg/ml (volume per well=100 μl). The selective
PPARα antagonist GW6471 [(2S)-2-[[(1Z)-1-Methyl-3-
oxo-3-[4-(triﬂuoromethyl)phenyl]-1-propenyl]amino]-3-
[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxyphenylpropyl-
carbamic acid ethyl ester] (Tocris-Bioscience, UK) was
used at 1 μM dissolved in 10% DMSO.
In vivo study
Microdialysis of extracellular OEA
Seven male Wistar rats were anaesthetized with an
isoﬂurane/oxygen vapour mixture (1.5–2.0%) and placed
in a stereotaxic apparatus. A guide cannula (SciPro, USA)
was aimed at the dorsal striatum for each animal
(Bregma: anterior–posterior, +1.0 mm; medial-lateral,
±2.6 mm; dorsal-ventral, −3.1 mm) (Paxinos and Watson,
2007). Afterwards, the animals received a minimum of
5 d of post-operative recovery before microdialysis.
During the microdialysis experiment, each animal
was lightly anaesthetized (1–2% isoﬂurane), and a micro-
dialysis probe (2mm polyethyl sulfone membrane,
15 kDa MW cut off; SciPro) was inserted and secured to
the guide cannula. The probes were perfused with artiﬁ-
cial cerebrospinal ﬂuid (aCSF) delivered at a 0.6 μl/min
ﬂow-rate. Approximately 6 h after the probe implan-
tation, the dialysate samples were collected at 20min
intervals over a 60min baseline period and during a sub-
sequent post-treatment (OEA, 20mg/kg) period.
Liquid chromatography/mass spectrometry analysis
The dialysate level of OEA was determined using liquid
chromatography coupled with electrospray ionization
mass spectrometry (Agilent 1100 LC-MS Single Quadru-
pole Mass Spectrometer, Agilent, USA). Previously, exter-
nal calibration curves were constructed from a minimum
of three standard chromatographic concentrations pre-
pared in duplicate, daily. For the dialysate samples, 5 μl
of the microdialysate aliquots were spiked with 5 μl of
25 nM of S-2 methanandamide as an internal standard.
The standards and samples were loaded onto a microbore
precolumn using a 10% methanol (v/v) mobile phase
delivered at 55 μl/min by a pump. After a washing period,
the mobile phase ﬂow through the precolumn was re-
versed via a switching valve, and the compounds
were delivered to a microbore analytical column using
another isocratic mobile phase delivered at 9 μl/min.
The following mass/charge (m/z) ratios were used:
anandamide (AEA), 370.3 (molecular ion (M)+1
Na); 2-arachidonoylglycerol (2-AG) and 1-arachidonoyl-
glycerol (1-AG), 401.3 (M+1 Na); palmitoylethanolamide
(PEA), 322.3 (M+1 Na); oleoylethanolamide (OEA),
348.3 (M1+Na); methanandamide (S-2), 384.3 (M+1 Na).
Under these proposed analytical conditions, the limits
of quantitation were approximately 0.1 nM for each
analyte. During the analysis of the data, the peak areas
of interest were calculated considering the internal control
S-2 methanandamide and the obtained ratios. The ratios
were related to the concentrations of the standard curve
with known concentrations.
In vivo 6-OH-DA-induced striatal lesions
To assess the neuroprotective effects of OEA, we per-
formed the retrograde classic model of experimental
Parkinsonism induced by a 6-OH-DA lesion (Ungerstedt,
1968). Thirty minutes before the 6-OH-DA-induced
lesions, the rats were injected i.p. with desipramine
(15mg/kg) and citalopram (1mg/kg; Sigma-Aldrich) to
protect the noradrenergic and serotonergic terminals
from 6-OH-DA toxicity, respectively. The rats were anae-
sthetized (ketamine, 50mg/kg and xylazine, 10mg/kg,
IM, Sigma-Aldrich) and placed in a Kopf stereotaxic ap-
paratus. A solution containing 6-OH-DA (5 μg/μl) was
injected (each μl was infused during 150 s) with a blunted
30-gauge cannula into the dorsal striatum. The sterotaxic
coordinates of the dorsal striatum relative to Bregma
were: (1) (4 μl): anterior–posterior=+1.6, medial–lateral
=−2.6, dorsal–ventral=−5.2 mm; (2) (4 μl): anterior–
posterior=+0.5, medial–lateral=−3.0, dorsal–ventral=
−5.5 mm; (3) (2 μl): anterior–posterior=−1.3, medial–
lateral=−4.0, dorsal–ventral=−5.0mm (Paxinos and
Watson, 2007). The cannula was left in place for 1 min
to allow diffusion of the solution after each injection.
Behavioural study
Motor deﬁcits were evaluated 1 and 4 wk after the uni-
lateral striatal lesion or sham operation, according to
methodology previously described (Ungerstedt and
Arbuthnott, 1970; Schwarting and Huston, 1996;
Fernandez-Espejo et al., 1998; El-Banoua et al., 2004;
Galan-Rodriguez et al., 2009). The motor tasks included
locomotor directional bias, altered spontaneous loco-
motion (akinesia and bradykinesia), and forelimb asym-
metry. Locomotor directional bias was evaluated by
quantifying the rotations induced by acute amphetamine
(5mg/kg, i.p.) and apomorphine (0.5 mg/kg, i.p.). The
number of ipsiversive turns was quantiﬁed over 60min
beginning 30min after the amphetamine injection, and
only those animals who were observed to make more
than 420 turns/h were selected. The apomorphine test
was carried out the following day, and the number of
contralateral turns was quantiﬁed over 60min beginning
5min after the injection. Spontaneous locomotion (akine-
sia and bradykinesia) was evaluated in the locomotion
cages (45×45 cm) for 10min. Akinesia was measured by
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the distance travelled, and bradykinesia was evaluated by
the mean speed of movements. The behaviour was video-
taped and analysed with a Smart video-tracking system
(Panlab, Spain). Forelimb asymmetry was evaluated by
the cylinder test (Kirik et al., 2000), where the animal
is allowed to move freely in a transparent cylinder (50×
30 cm) for 10min, and rearing postures were observed.
The number of left and right forepaw contacts was
counted, and the data are presented as the percent right
forepaw contacts (right forepaw use ratio). Hemi-
Parkinsonian rats with a lesion in the left dorsal striatum
present a signiﬁcant impairment in the contralateral
(right) forepaw use, which is indicative of forepaw use
asymmetry.
Immunohistochemistry
Brain mesencephalic sections (40 μM) were obtained with
a cryostat (Micron, USA) and subjected to TH immuno-
staining (n=6 per group). Brieﬂy, all the sections were
incubated overnight with monoclonal mouse anti-TH
(1:1000; Sigma-Aldrich) in Phosphate Buffered Saline
(PBS) with Triton-X100. On the next day, after PBS wash-
ing, sections were incubated for 5 h with a biotinylated
anti-mouse antibody (1:200; Sigma-Aldrich). Then, the
sections were incubated with the Vectastain ABC kit
(1:100; Vector, USA) for 2 h, and the speciﬁcally bound
antibodies were revealed using 3, 3′-diaminobenzidine
(Sigma-Aldrich) as the chromogen with 0.01% hydrogen
peroxide. Finally, the tissue sections were washed in
PBS, mounted on glass slides and coverslipped.
Density of the striatal TH+ innervations
The optical density of striatal TH+ innervation was mea-
sured at coronal serial sections (8–12 per rat). The images
from the sections including both striata were taken with a
digital camera from a microscope (Olympus, Japan). The
images were analysed using Scion-Image for Windows
(freeware version). The mean density of the entire stria-
tum was calculated. The values are also presented as
the mean percentage TH+ density in the lesioned striatum
vs. the contralateral non-lesioned striatum (considered as
100%).
Stereology
The methodology for stereological measurement
was based on Aguirre and colleagues (Aguirre et al.,
1999). The fractionator and optical dissector methods
(Gundersen et al., 1988) were used to estimate the total
number of TH+ neurons. Stereological measurements
were performed using the CAST-Grid software
(Olympus, Germany). This software package generated
sampling frames with a known area, and directed the
motorized X–Y stage (LANG GmbH &Co. KG,
Germany) and a MT-12 microcator (Heidenhain Co.,
Germany) which monitored the movements in the
Z-axis with a resolution of 0.5 mm. The substantia nigra
pars compacta (SNpc) of each 40 μM section ( tˉ ) was deli-
neated using a 4 × objective. The CAST-grid software pro-
duced a set of crosses, the Cavalieri or hitting points,
which were counted using the appropriate counting cri-
teria (Lagares and Avendaño, 1999). The area associated
with each point (a(p)) was 23 767.7 μM2. The estimated vol-
ume (V) of the SNpc was calculated as follows (Aguirre
et al., 1999; Lagares and Avendaño, 1999):
V = ΣPi× a( p) × tˉ× n
where ΣPi= total number of hitting points; n=number of
sections. The estimated number of neurons was counted
using a 20 × objective. The system produced a serial of
frames, the ﬁrst one being placed randomly, and the re-
mainder frames were placed following a random system-
atic arrangement (Sterio, 1984). The frame size was 15%
of the observation area, and the sampling covered 20%
of the SNpc. The distance between two adjacent sections
was tˉ=160 μM. The associated area of each frame (a(ret))
was 21 391 μM2. First, the estimated dissector volume
(V(dis)) was calculated as follows:
V dis( ) = a ret( ) × number of counting frames, tˉ
Second, the estimated total number of neurons (N) was
calculated as follows (Gundersen et al., 1988; Aguirre
et al., 1999), according to the following formula:
N = ΣQ− × V(ref)/V(dis)
where ΣQ−= total number of cells counted; V(ref)=esti-
mate of the volume; V(dis)=estimated dissector volume
(Gundersen et al., 1988). The coefﬁcient of error (CE) for
each estimation and animal ranged from 0.01 to 0.05.
The total CE for each group (CE group value) ranged
from 0.02 to 0.04. The mean volume of the TH-immuno-
reactivity (ir) neurons was estimated by means of the
point sampled intercept method based on Cavalieri’s
principle (Gundersen et al., 1988). The estimations of
the mean volume are obviously inﬂuenced by shrinkage,
which was close to 50%, and the volume results were
multiplied by 2.
Protein immunoblotting
Other groups of Parkinsonian rats (n=4 per group)
were used for western blotting analysis. These rats were
subjected to the same OEA and 6-OH-DA regimen as
explained previously and were sacriﬁced 48 h after the
lesion to study the striatal heme-oxygenase 1 (HO-1)
and synaptophysin expression. The brains were removed
from decapitated rats and cooled in ice-cold physiological
buffer. Both dorsal striata were obtained by careful dis-
section under microscopic observation. The brain samples
were lysed, and the protein levels were quantiﬁed
using the Bradford method (Bradford, 1976). Samples
containing 25 μg of protein each, were subjected to so-
dium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE). The proteins were electrophoretically
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transferred to polyvinylidene diﬂuoride (PVDF) mem-
branes. Immunolabelingwas conductedwith goat polyclo-
nal anti-HO1 (1:500; Santa Cruz, USA), mousemonoclonal
anti-synaptohysin (1:1000; GmbH, Germany), and mouse
monoclonal anti-α-actin antibody (reference protein;
Santa Cruz). The primary antibodies were detected with
peroxidase-linked secondary antibodies (Santa Cruz)
with enhanced chemiluminescence (Amersham-GE,
Sweden) and autoradiography. The band densities were
quantiﬁed using the Scion-Image. The values are given
as a percentage band density with respect to the corre-
sponding striatum of rats injected with vehicle (con-
sidered as 100%).
In vitro study
Neuron culture
Primary cultures of substantia nigra neurons were es-
tablished as previously described by Cardozo (1993),
with some modiﬁcations (Mena et al., 1997; Burke et al.,
1998; Smeyne and Smeyne, 2002). Postnatal pups (PD0)
were killed by decapitation, and the brains were removed
and placed in cold Hank’s balanced salt solution (GIBCO,
USA). Under a dissecting microscope, a 0.8–1.0 mm thick
coronal section of the mesencephalon was made using a
scalpel, and the regions containing the substantia nigra
were isolated. The tissue was digested in a solution of
papain (20 units/ml; Worthington, USA) with 0.2mg/ml
L-cysteine in Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM; Sigma-Aldrich), 100mM CaCl2, and 50mM
EDTA for 40min at 37 °C in an incubation bath.
Afterwards, the tissue was mechanically dissociated and
centrifuged (1000 r/min) for 5min. The pellet was col-
lected and layered on top of the inactivation medium.
The pellet was resuspended with feeding medium con-
sisting of Neurobasal®-A supplemented with 2% B-27®
and 1% Glutamax (Life Technologies, USA), and cell
counts were made. The cell suspension was adjusted to
30000 cells per well in a standard 96-well plate.
6-OH-DA/OEA cell culture treatment and lactate
dehydrogenase (LDH) assay
The exposure to 6-OH-DA was initiated after 4–5 d
in vitro. The medium was removed and changed to
Neurobasal® without B-27® for 2 h (Molina-Holgado
et al., 2005). OEA (0.5, 1, and 5 μM in 1% DMSO in
Neurobasal®) was added to the neurons before and
after the treatment with 6-OH-DA for 2 h. The time and
dose are based on Su and colleagues (Su et al., 2006).
Freshly prepared, 6-OH-DA (40 and 60 μM) with 0.15%
ascorbic acid in saline was added for 15min to induce
speciﬁc death of the dopaminergic neurons (Ding et al.,
2004). The medium was removed immediately after
6-OH-DA or 2 h after 6-OH-DA for OEA treatment.
Next, the cultures were gently washed, twice, with
Neurobasal® and then further incubated for 24 h to per-
form the lactate dehydrogenase (LDH) assay. If GW6471
was used, it was added to the medium for 15min just
before 6-OH-DA (1 μM), and OEA was given after the
insult. Cytotoxicity was evaluated by the release of the
cytosolic enzyme, LDH, into the culture medium by
dead and dying cells (Cytotoxicity Detection kit; Roche,
Germany). The total LDH release was calculated by incu-
bating untreated cells with 0.5% Triton X-100 for 1 h to in-
duce maximal cell lysis. The basal death was calculated
from untreated wells without B-27®. The treatment values
were expressed as a percent of the maximal LDH release.
Statistical analyses
Two-way analysis of variance (ANOVA) was used for
analysing behaviour, striatal density, stereological results
and cell culture data, followed by the post-hoc Newman–
Keuls test for comparisons among groups, or Student’s
t-test to compare two groups. With respect to western
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Fig. 1. Dorsal striatum OEA dialysate concentration (nM) before and after systemic OEA administration (20mg/kg, i.p.), as
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blotting, the density of the bands was compared with the
non-parametric Kruskal–Wallis test followed by the post-
hoc Wilcoxon test. In all cases, when the variance was not
homogeneous, the data were logarithmically (log(x))
transformed prior to analysis (Gravetter and Wallnau,
2007).
Results
OEA crosses the blood–brain barrier as revealed by
monitoring its interstitial concentration in dorsal
striatum after systemic administration
The ﬁrst experiment was designed to conﬁrm that OEA
injected peripherally can cross the blood–brain barrier.
Figure 1 shows the extracellular levels of OEA in the dor-
sal striatum after a single i.p. injection of OEA (20mg/kg).
Baseline levels of OEA were established for 1 h at 20min
sampling intervals and the concentrations were as follow:
49.69±13.07 nM (60–40min pre-injection), 57.12±18.34 nM
(40–20min pre-injection) and 54.50±15.20 nM (20–0min
pre-injection) (N=7). The peripheral administration of
OEA induced an increase in the interstitial levels of
OEA obtained by microdialysis. In fact, the maximum
peak was reached after the OEA injection: 157.28±
53.66 nM at 20min post-injection (p<0.01). This OEA
concentration reached at 20min post-injection (157.28±
53.66 nM) is within the range reported to produce
stimulation of PPARα receptor-dependent transcription
(120 nM) (Fu et al., 2003). These results show that OEA
rapidly crosses the blood–brain barrier increasing its extra-
cellular concentrations, although a fast clearance occurs
thereafter. Such increasewas followed by a rapid clearance
(87.08±19.56 nM, at 40min post-injection). However, the
dialysate levels after 60min remained slightly above
the baseline (93.85±21.84 nM at 60min; 86.09±15.40 nM
at 80min; 76.29±12.05 nM at 100min; 75.35±14.46 nM at
120min; 77.30±10.70 nM at 140min; 76.86±12.01 nM at
160min post-injection), although these values were not
different when compared to the baseline (Bonferroni post
hoc test). Additionally, we have now provided statistical
data byone-wayANOVAshowing the stability of the base-
line of OEA levels that were evaluated at 60–40, 40–20 and
20–0min before OEA injection to show no differences in
baseline OEA dyalisates (F2,18=0.05, p=0.9). This kinetics
is similar to the observed in plasma after peripheral admin-
istration of OEA (Rodriguez de Fonseca et al., 2001).
OEA given systemically signiﬁcantly reduces
behavioural Parkinsonian symptoms
In order to evaluate the potential neuroprotective actions
of OEA, we measured the onset of Parkinsonian symp-
toms in animals treated with either OEA, 6-OH-DA or its
combination. Regarding amphetamine-induced rotations,
two-way ANOVA revealed a signiﬁcant interaction effect
(F3,75=6.5, p<0.05). Post-hoc analysis revealed that number
of rotations were signiﬁcantly lower in animals treated
with 5mg/kg OEA relative to the other groups, at both
time point (1 and 4 wk, p<0.05) (Fig. 2(a)). Two-way
ANOVA also revealed a signiﬁcant dose effect (F3,75 =
5.5, p<0.05) in apomorphine-induced rotations. But in
this case, post-hoc analysis revealed that number of rota-
tions were only signiﬁcantly lower in animals treated
with 5mg/kg OEA relative to the other groups, at 4 wk
post-lesion (p<0.05) (Fig. 2(b)).
Altered spontaneous locomotion was evaluated in
locomotion cages. Two-way ANOVA revealed signiﬁcant
interaction effects for speed of movement or bradykinesia
index (F3,62 =5.7, p<0.05) and distance traveled (akinesia;
F3,62=5.5, p<0.01). Post-hoc analysis showed that brady-
kinesia and akinesia were lower in those animals treated
with 5mg/kg OEA at both 1 and 4 wk after lesion (Fig. 3
(a, b)). Forelimb asymmetry was measured with the cylin-
der test. Two-way ANOVA indicated a signiﬁcant interac-
tion effect (F3,62=2.9, p<0.05). Post-hoc analysis revealed
that right forepaw use ratio was signiﬁcantly enhanced
in animals treated with 5mg/kg OEA relative to the
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Fig. 2. Amphetamine- and apomorphine-induced rotations in
rats treated with systemic OEA before or after 6-OH-DA
intrastriatal toxic insult. (a) Ipsiversive amphetamine-induced
rotations were reduced in animals receiving OEA 5mg/kg, at
both time points (1 wk, p<0.05; 4 wk, p<0.01).
(b) Contraversive apomorphine-induced rotations were
enhanced in each group over time, except for in the animals
treated with OEA 5mg/kg at 4 wk post-lesion (p<0.01). Mean
±S.E.M., *p<0.05; **p<0.01 vs. the other animals at the same time
point (Newman–Keuls). The data are expressed as the number
of rotations/hr.
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other groups, at 1 (t=2.9, p<0.01) and 4wk post-lesion
(t=2.1, p<0.05) (Fig. 3(c)).
OEA-induced neuroprotection: striatal TH density is
strongly reduced after 6-OH-DA infusion, but this
reduction is weaker if animals are treated with OEA
In order to conﬁrm if OEA helps to protect dopaminergic
neurons after 6-OH-DA insult, we measured the striatal
density of the TH enzyme. ANOVA indicated an inter-
action treatment×striatum effect on TH density
10
* *
* **
**
*
8
6
4
2
0
1 wk 4 wk
Time point
M
ea
n 
sp
ee
d 
of
 
m
ov
em
en
ts
 (c
m
/s
)
Control
0.5 mg/kg OEA
1 mg/kg OEA
5 mg/kg OEA
5000
4000
3000
2000
1000
0
1 wk 4 wk
Time point
D
is
ta
nc
e 
tr
av
el
le
d 
(c
m
)
60
Normal ratio
50
30
40
20
10
0
1 wk 4 wk
Time point
R
ig
ht
 fo
re
pa
w
 u
se
 r
at
io
(a)
(b)
(c)
Fig. 3. Spontaneous motor tests in rats treated with systemic
OEA before or after 6-OH-DA intrastriatal toxic insult. Both,
(a) Bradykinesia (mean speed of movements (cm/s)) and
(b) akinesia (distance traveled (cm)) measured in an open ﬁeld,
were signiﬁcantly attenuated in animals receiving OEA at
5mg/kg at both time points (1 wk, p<0.05; 4 wk, p<0.05 and
p<0.01). (c) Forepaw asymmetry (right forepaw use ratio), as
measured by the cylinder test, was signiﬁcantly lower in
animals treated with OEA at 5mg/kg at 1 wk (p<0.05) and
4 wk post-lesion (p<0.01). Mean±S.E.M., *p<0.05; **p<0.01 vs.
the other animals at the same time point (Newman–Keuls).
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Fig. 4. Striatal TH immunostaining density (TH+ density).
Top: Representative photomicrographs of the striatum at
different levels with TH immunostaining. The left striatum (L)
was injected with 6-hydroxydopamine, and the animals
were treated with systemic vehicle (control) or OEA (0.5,
1 and 5mg/kg doses). 4 wk later, a strong reduction of
TH-positive signal was observed in the vehicle-treated
hemi-Parkinsonian animals as well as the animals treated with
0.5mg/kg OEA, however, this signal was reliably improved
after 1 and 5mg/kg OEA treatment. Bottom: Percent TH+
density values of the left striatal tissue relative to the
contralateral striatum of the vehicle-treated group (considered
as 100%, control). The percent TH density of the whole
striatum was reduced in the vehicle-treated and 0.5mg/kg
OEA-treated-Parkinsonian rats at 4 wk after 6-OH-DA
infusions relative to the normal contralateral striatum
(−45±8%, vehicle-treated, p<0.01; −27±8%, 0.5mg/kg
OEA-treated, p<0.05), but the percent striatal TH density was
not reliably reduced in animals that were treated with 1mg/kg
(−15±8%) or 5mg/kg OEA (−1±0.2% vs. contralateral
striatum). Mean±S.E.M., *p<0.05, **p<0.01 vs. contralateral
striatum (Wilcoxon test). Bar: 1 mm. Abbreviations: L, left:
R, right.
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(F4,49=8.9, p<0.01), as well as a treatment effect (F3,49 =
12.4, p<0.02) suggesting a neuroprotective effect. Percent
TH density of the whole striatum was found to be re-
duced in vehicle-treated and 0.5 mg/kg OEA-treated-
Parkinsonian rats at 1 and 4 wk after 6-OH-DA infusions
relative to normal contralateral striatum (−55±8%,
vehicle-treated; −31±8%, 0.5mg/kg OEA-treated; p<
0.01), but percent striatal TH density was not reliably
reduced if animals were treated with 1mg/kg (−4±1%)
or 5mg/kg OEA (−1±0.2% vs. contralateral striatum), as
shown in Fig. 4.
OEA-induced neuroprotection: the number of TH+
neurons in the substantia nigra is signiﬁcantly reduced
after intrastriatal 6-OH-DA infusion, and it was less
severe following treatment with OEA
The neuroprotection induced by OEA were also observed
when the number of substantia nigra neurons was moni-
tored after 6-OH-DA insult. Two-way ANOVA revealed
a signiﬁcant interaction effect on number of TH+ neurons
in the substantia nigra of Parkinsonian groups (F1,19 =
78.9, p<0.001). The number of TH+ cells was lower in
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Fig. 5. Nigral TH immunostaining density (TH+ density). Top: Representative photomicrographs of the substantia nigra at different
levels following TH immunostaining. The left striatum was injected with 6-hydroxydopamine, and the animals were treated with
systemic vehicle (control) or OEA (0.5, 1 and 5mg/kg doses). 4 wk later, a strong reduction of TH+-expressing cells is observed in
the left substantia nigra of vehicle-treated hemi-Parkinsonian animals as well as the animals treated with 0.5 and 1mg/kg OEA;
however, the number of TH+ neurons was signiﬁcantly less reduced after administration of 5mg/kg OEA. Bottom: Percent reduction
in the number of TH+ cells in the substantia nigra relative to the contralateral substantia nigra of the vehicle group (considered as
100%, control). The percentage reduction of 5mg/kg OEA-treated rats (−17.2±2%) was signiﬁcantly lower (p<0.05) than that of the
remainder of the hemi-Parkinsonian groups (vehicle, −52.1±6%; 0.5mg/kg OEA, −56.1±6%; 1mg/kg OEA, −35.5±7%; p<0.01).
Mean±S.E.M., *p<0.05, **p<0.01 vs. contralateral substantia nigra of controls; #p<0.05 vs. the other groups treated with OEA or
vehicle (Wilcoxon test). Bar: 1 mm. Abbreviations: L, left: R, right.
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all Parkinsonian rats comparing TH+ neurons/mm3 con-
tralateral vs. lesioned side: vehicle-treated (6676±1432
vs. 3237±1476), 0.5mg/kg OEA (7643±1083 vs. 2968±
782), 1 mg/kg OEA (7841±900 vs. 4362±1293), and
5mg/kg OEA (7484±551 vs. 5600±644). However, con-
sidering corresponding contralateral substantia nigra as
control (100%), statistical study revealed that percentage
reduction of 5mg/kg OEA-treated rats was signiﬁcantly
lower (−23±4%, p<0.05) than vehicle-, 0.5 and 1mg/kg
OEA-treated groups (vehicle, −44±5%; 0.5mg/kg OEA,
−39±6%; 1mg/kg OEA, −31±6%) (Fig. 5).
OEA improves additional biomarkers of lesion:
analysis of HO-1 and synaptophysin
HO-1 expression is enhanced in the 6-OH-DA-lesioned
striatum except following treatment with OEA
The Kruskal–Wallis test revealed a signiﬁcant interaction
effect on HO-1 expression (H=7.8, p<0.05). Post-hoc
analysis indicated that HO-1 expression was signiﬁcantly
enhanced in all striata of Parkinsonian rats (vehicle, +86±
4%; 0.5mg/kg OEA, +76±9%; 1mg/kg OEA, +53±13%;
p<0.01 vs. corresponding normal contralateral striatum),
and this reduction was signiﬁcantly lower in 5mg/kg
OEA-treated rats (+5±17% vs. contralateral one).
Increased HO-1 expression in 5mg/kg OEA-treated rats
was signiﬁcantly lower than that of the remaining
Parkinsonian groups (p<0.05), as shown in Fig. 6.
Synaptophysin content is reduced in the 6-OH-DA-lesioned
striatum except following treatment with OEA
Two-way ANOVA revealed a signiﬁcant interaction
effect on synaptophysin expression (F3,14=6.3, p<0.01).
Post-hoc analysis indicated that synaptophysin expression
was signiﬁcantly reduced in striata of Parkinsonian rats
(vehicle, −17±4%; 0.5mg/kg OEA, −14±3%; 1mg/kg
OEA, −10±2%; p<0.05 vs. corresponding contralateral
striatum), and this reduction was not observed in
5mg/kg OEA-treated rats (1±2% vs. contralateral one),
as shown in Fig. 6.
Mechanisms of action: 6-OH-DA-induced death of
cultured substantia nigra dopaminergic neurons is
attenuated by in vitro 0.5 and 1 μM OEA and
reversed by the PPARα agonist GW6471
OEA in culture produced neuroprotection against 6-OH-
DA-induced insult. Two-way ANOVA revealed a signiﬁ-
cant interaction OEA×6-OH-DA effect (F6,71 =4.9, p<
0.05), as well as OEA (F3,71=78, p<10
−6) and 6-OH-DA ef-
fects (F6,71=99, p<10
−6). Post-hoc analyses indicated that
cell death, as measured through the LDH signal, was
signiﬁcantly lower in three groups: 6-OH-DA 40 μM
+OEA 0.5 μM (t=2.3, p<0.05); 6-OH-DA 40 μM+OEA 1 μM
(t=2.4, p<0.05), and 6-OH-DA 60 μM+OEA 1 μM (t=3.5,
p<0.05), all relative to the corresponding 6-OH-DA
alone group (Fig. 7(a)). OEA-induced effects followed
U-shaped curves, with the highest OEA dose (5 μM) in-
ducing signiﬁcant cell death in its own right (Fig. 7(a)).
In order to test whether OEA actions depend on
PPARα receptor, cell death was tested in the presence of
the selective antagonist GW6471. Basal cell death was
not affected in culture neurons after pretreatment with
GW6471 (Fig. 7(c)). Regarding OEA-induced effects, two-
way ANOVA did not indicate a signiﬁcant interaction
effect, but showed a dose effect (F3,71 =55; p<5×10
−5).
On the other hand, OEA-induced neuroprotection of
6-OH-DA-treated cells was abolished, and 5 μM OEA-
induced cytoxicity was not eradicated in these cells as
measured through the LDH test.
Discussion
In the present study, the potentially neuroprotective
efﬁcacy of systemically administered OEA in a model
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Fig. 6. Representative immunoblots showing the expression signal of HO-1, synaptophysin, and control α-actin in both striata
(lesioned with 6-OH-DA and normal), after the OEA treatments (vehicle and 0.5, 1 and 5mg/kg OEA). Below each panel, the
percent density values relative to the corresponding contralateral striatum (considered as 100%) are shown. Mean±S.E.M., *p<0.05,
**p<0.01 vs. vehicle-treated lesioned striatum of hemi-Parkinsonian rats.
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of neurotoxin-induced Parkinsonism was assessed. OEA
administered by i.p. injection can cross the blood brain
barrier and reach active concentrations in the basal gang-
lia (Fig. 1). At this concentration, OEA can target PPARα
receptors and produce anti-inﬂammatory/antioxidant
responses. This ﬁnding is relevant because the in vivo
model selected in the present study was based on the
neurotoxin 6-OH-DA, which induces rapid oxidative
and inﬂammatory responses in the striatum (Tatton and
Kish, 1997; Mogi et al., 2000; Nagatsu and Sawada,
2005) and progressive cell death in the substantia nigra
(Munoz et al., 2005; Rey et al., 2007), leading to overt
Parkinsonian symptoms. This model provides a method
for better discerning the potentially neuroprotective ef-
fects (Sauer and Oertel, 1994; Przedborski et al., 1995).
The present ﬁndings revealed that 5mg/kg OEA ad-
ministered i.p. was able to reliably reduce behavioural
deﬁcits in Parkinsonian rats, including motor asymme-
tries, forepaw use asymmetry and akinesia/bradykinesia.
Doses of 0.5 and 1 μM (given after 6-OH-DA insult) were
able to antagonize the damage in cell culture of substantia
nigra neurons. The functional effects are indicative of an
effective antagonism to dopamine depletion caused by
6-OH-DA, while the cellular effects seem to be mediated
by PPARα. OEA can exert its effects on nigral dopamine
neurons because the nuclear receptors, PPARα, are ex-
pressed by dopamine neurons of the substantia nigra
and the intrinsic neurons of the dorsal striatum (Kainu
et al., 1994; Cullingford et al., 1998; Moreno et al., 2004;
Galan-Rodriguez et al., 2009).
Systemic 5mg/kg OEA was able to induce long-term
neuroprotection in the nigrostriatal circuit, and the
severe reduction of striatal TH observed after 6-OH-DA
was reliably attenuated after this dose but not with the
other doses. This result conﬁrms that OEA exerts anti-
Parkinsonian and neuroprotective effects within a narrow
dose range, as observed in our previous work (Galan-
Rodriguez et al., 2009), where OEA was locally adminis-
tered. OEA-induced neuroprotection followed U-shaped
dose response curves with beneﬁcial effects at low
doses (Galan-Rodriguez et al., 2009) and toxicity due to
a high drug concentration at the high dose (Calabrese
and Baldwin, 2001). Dopamine cell death in the substan-
tia nigra was clearly reduced because a higher number of
dopamine cells survived long-term after the toxic insult
following administration of systemic 5mg/kg OEA. This
dose also reduced a short-term oxidative response in
the dorsal striatum, as measured through HO-1. HO-1
was employed as a marker for oxidative stress (Munoz
et al., 2005), and its expression is strongly induced after
oxidant and noxious stimuli (Applegate et al., 1991).
Moreover, systemic administration of 5mg/kg OEA was
also effective in antagonizing the 6-OH-DA-induced re-
duction of the synaptophysin level within the striatum.
Synaptophysin is a major integral membrane protein of
small presynaptic vesicles and is used as a molecular
indicator for synaptic density (Marqueze-Pouey et al.,
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Fig. 7. Bars represent the percentage of cell death in cultured
neurons of the substantia nigra after different treatments, as
evaluated through the LDH test. (a) OEA added to cell culture
before 6-OH-DA-induced insult at 0.5 and 1 μM concentrations
does not protect cells. (b) OEA added to cell culture before
6-OH-DA-induced insult at 0.5 and 1 μM concentrations protects
against 6-OH-DA-induced insult at 0.5 and 1 μM concentrations
on cells treated with 40 or 60 μM 6-OH-DA (p<0.05).
The deleterious effect of 5 μM OEA can also be observed.
(c) GW6471 treatment (1 μM) before OEA given after insult was
able to block the neuroprotective effects of OEA. Mean±S.E.M.,
*p<0.05 vs. groups without OEA (Student’s t-test).
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1991). 6-OH-DA destroys dopaminergic terminals and re-
duces synaptic contacts, leading to a signiﬁcant reduction
of synaptophysin. The neuroprotection achieved by
5mg/kg OEA indicates that the integrity of dopaminergic
terminals was maintained after this OEA dose. In this
sense, OEA could exert these effects by way of central
actions because: (1) OEA crosses the brain blood barrier
after peripheral injection (Plaza-Zabala et al., 2010),
(2) OEA has been reported to exert neuroprotective
actions after intracerebral (striatum) injection (Galan-
Rodriguez et al., 2009), (3) PPARα has been extensively
reported to be expressed in the brain (Kainu et al., 1994)
including mesolimbic circuitries, (4) without discarding
other molecular targets of OEA, the activation of
PPARα is also known to induce neuroprotective effects
(Deplanque et al., 2003) and (5) here, OEA exerts neuro-
protection in cultured neurons and this action is pre-
vented with PPARα antagonists.
Regarding the in vitro study, OEA protected cultured
substantia nigra dopamine neurons from 6-OH-DA-
induced toxicity at 0.5 and 1 μM doses. The protective ef-
fects also followed U-shaped curves, with the highest
OEA dose (5 μM) being ineffective in all cases and even in-
ducing cytotoxicity of cultured neurons. In this context, a
U-shaped curve normally suggests a pleiotropic effect
that could be due to the existence of two different popu-
lations of receptors because this type of curve is well de-
scribed by two exponential functions (Meuth et al., 2002).
In fact, the protective effects disappeared when the cell
culture was treated with GW6471, a selective antagonist
of PPARα. Hence, the ﬁndings can be accounted for by
a neuroprotective effect mediated by OEA through
PPARα. An alternative explanation is that opposing intra-
cellular pathways are activated by different OEA doses,
because biphasic responses to lipid transmitters have
been noted in several studies (Okada et al., 1992; Glass
and Felder, 1997; Sulcova et al., 1998).
The molecular mechanisms through which OEA
exerts dose-dependent neuroprotective effects in vivo
may well be diverse. OEA actions can mimic the protec-
tive and antioxidant actions of PPARα agonists, such as
the ﬁbrates (Deplanque et al., 2003). It is known that
fenoﬁbrate and bezaﬁbrate exert neuroprotective effects
in Parkinsonian mice after MPTP insult (Kreisler et al.,
2007), and fenoﬁbrate treatment is known to favourably
modulate the oxidant–antioxidant balance (Beltowski
et al., 2002). The activation of PPARα induces neuropro-
tective effects also involving both cerebral and vascular
mechanisms (Bordet et al., 2006). Activation of the main
family of PPAR receptors (both α and γ isoforms) de-
creases neuronal death through a vascular protection,
and these vascular effects result from a decrease in oxidat-
ive stress and prevention of adhesion proteins (Bordet
et al., 2006). Apoptosis and inﬂammation are also regu-
lated by PPARα, whose activation negatively regulates
the transcription of inﬂammatory response genes by
antagonizing the AP-1 and nuclear factor-κB signaling
pathways (Schmidt et al., 1999; Delerive et al., 2001;
Lleo et al., 2007).
In summary, we have demonstrated that systemic ad-
ministration of OEA, an endogenous PPARα agonist,
dose-dependently protects the nigrostriatal circuit from
6-OH-DA-induced toxicity as well as dopamine neurons
in culture subjected to oxidative stress. These effects
open the possibility of reducing the impact of nigrostriatal
neurodegeneration by targeting PPARα receptors with a
natural agonist.
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